| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbae684c01e866958496a909712f218d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5153
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5153
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-549 |
| filingDate |
2019-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f725373382ddf2678efd98e33e8795d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36c71f1b15d8b55340625616f55e1087 |
| publicationDate |
2021-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3843745-A1 |
| titleOfInvention |
Methods and compositions for treating neuroblastoma in a juvenile mammalian body |
| abstract |
Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. This invention relates to the use of taurolidine for the treatment of neuroblastoma in juvenile mammals. |
| priorityDate |
2018-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |